O'Melveny's Zucker Discusses Government Efforts to Spur Biomedical Innovation in Daily Journal Article
O'Melveny Mergers and Acquisitions Practice Group partner Sam Zucker was quoted in a
Daily Journal article discussing ways to boost biomedical industry innovation and create jobs in the sector. Zucker, who practices in the Firm's Silicon Valley office, told the paper that investors would benefit most from legislation like the 1983 Orphan Drug Act, which "gave companies faster regulatory pathways and longer periods before they faced generic competition if they developed medicines for diseases without effective treatments." In the October 19, 2011 article," Biotechs urge expedited review," Zucker says: "There are companies pursuing diseases that they wouldn't normally have pursued or that they wouldn't have gotten funding for without the Orphan Drug Act. If [investors] can get greater comfort on time to approval and time to market, that lowers their risk profile and therefore increases their return and makes it more viable for investors to invest."
October 20, 2011
Related Offices
Silicon Valley
Contacts
Sam Zucker
szucker@omm.com
+1-650-473-2638